Cumberland Pharmaceuticals and Gloria Pharmaceuticals Announce R&D Investment - - BioPharm International

ADVERTISEMENT

Cumberland Pharmaceuticals and Gloria Pharmaceuticals Announce R&D Investment



Cumberland Pharmaceuticals and Gloria Pharmaceuticals reported a joint R&D initiative. Each company has made a $1 million investment in Cumberland Emerging Technologies (CET), which is majority owned by Cumberland and partners with academic research centers to develop biopharmaceutical technologies. The new funds will be used to accelerate development of CET's pipeline of new product candidates from Vanderbilt University and other regional research centers.

CET was established by Cumberland Pharmaceuticals, Vanderbilt University, and the state of Tennessee to support the development of biopharmaceutical product candidates. Gloria will have the first opportunity to negotiate a license to CET products for China, and Cumberland will retain access to CET's product rights for the rest of the world.

Source: Cumberland Pharmaceuticals

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines

Click here